Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Debt Repayments (2022 - 2025)

Historic Long-Term Debt Repayments for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $4.0 million.

  • Indivior Pharmaceuticals' Long-Term Debt Repayments rose 30000.0% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.0 million, marking a year-over-year increase of 86153.85%. This contributed to the annual value of $240.0 million for FY2024, which is 190000.0% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Long-Term Debt Repayments stood at $4.0 million, which was up 30000.0% from $4.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $238.0 million during Q4 2024, with a 5-year trough of -$11.0 million in Q1 2023.
  • For the 4-year period, Indivior Pharmaceuticals' Long-Term Debt Repayments averaged around $24.4 million, with its median value being $4.0 million (2025).
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first changed by 0.0% in 2023, then surged by 89166.67% in 2024.
  • Over the past 4 years, Indivior Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $5.0 million in 2022, then skyrocketed by 380.0% to $24.0 million in 2023, then skyrocketed by 891.67% to $238.0 million in 2024, then crashed by 98.32% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.0 million for Q2 2025, and $4.0 million during Q1 2025.